Neuroleptic-induced deficit syndrome
Syndrome of negative symptoms caused by antipsychotic drugs.
Neuroleptic-induced deficit syndrome (NIDS) is a psychopathological syndrome that develops in some patients who take high doses of a neuroleptic (antipsychotic) drug for an extended time. It is most often caused by high-potency typical antipsychotics, but can also be caused by high doses of many atypicals, especially those closer in profile to typical ones. The concept was initially presented for schizophrenia and has rarely been associated in other mental disorders, though recent studies have examined it in bipolar disorder patients.
- Field
- Psychiatry
- Known for
- Psychopathological syndrome induced by antipsychotic drugs
- First described
- 1975 (as akinesia by Arthur Rifkin and colleagues)
- Term coined
- 1993 (First International Meeting on Neuroleptic Induced Deficit Syndrome, chaired by Malcolm Lader)
Lore & Background
Before the term NIDS was coined, the cluster of signs and symptoms was described using various labels such as 'drug-induced akinesia', 'neuroleptic dysphoria', 'neuroleptic-induced anhedonia' and 'pharmacogenic depression'. Arthur Rifkin and his colleagues systematically described the key symptoms now associated with NIDS in their 1975 paper 'Akinesia: A Poorly Recognized Drug-Induced Extrapyramidal Behavioral Disorder', presenting eight case histories and urging physicians to be more aware of the condition. The specific term 'neuroleptic-induced deficit syndrome' was born from an international meeting of psychiatrists and psychologists in 1993 chaired by Malcolm Lader, with proceedings published in 1994 as a supplement to Acta Psychiatrica Scandinavica.
Reader's Guide
Neuroleptic-induced deficit syndrome is principally characterized by the same symptoms that constitute the negative symptoms of schizophrenia: emotional blunting, apathy, hypobulia, anhedonia, indifference, difficulty or total inability in thinking, difficulty or total inability in concentrating, lack of initiative, attention deficits, and desocialization. There are significant difficulties in the differential diagnosis of primary negative symptoms and neuroleptic deficiency syndrome, as well as depression, which can easily lead to misdiagnosis and mistreatment—a 'prescribing cascade' where the doctor increases the antipsychotic dose instead of decreasing it. With the heavy marketing of second-generation antipsychotics starting in the mid-to-late 1990s, the pharmaceutical industry had no incentive to fund research into a syndrome implying their products caused cognitive harm, and NIDS research waned. In 2016, researchers from Nippon Medical School in Tokyo noted that the concept of NIDS appeared 'almost forgotten in current psychiatry' and called for a reappraisal of antipsychotic drugs and NIDS.
Did You Know?
- The term NIDS was coined at the 1993 First International Meeting on Neuroleptic Induced Deficit Syndrome, chaired by Malcolm Lader, with proceedings published in 1994.
- A Japanese man misdiagnosed with schizophrenia exhibited NIDS and obsessive–compulsive symptoms; his symptoms improved after quitting antipsychotics and starting the antidepressant fluvoxamine.
- Serbian television presenter Bojana Nikolić Janković died by suicide in 2024 after reporting symptoms consistent with NIDS following depot injections of paliperidone palmitate.
Frequently Asked Questions
Who is Neuroleptic-induced deficit syndrome?
NIDS is a cluster of negative psychiatric symptoms—emotional blunting, social withdrawal, reduced motivation—that emerges in patients after prolonged exposure to high doses of antipsychotic medication. It is not a standalone illness but a drug-induced overlay that can mimic or worsen the negative symptoms of schizophrenia.
What are Neuroleptic-induced deficit syndrome's powers/role?
Its clinical 'role' is to produce a flat, apathetic, and socially withdrawn state that closely resembles the negative symptoms of schizophrenia itself. It is most commonly triggered by high-potency typical antipsychotics, though sufficiently high doses of atypical agents with a more typical-like pharmacological profile can also precipitate it.
Why is Neuroleptic-induced deficit syndrome important?
It matters because it can be mistaken for treatment-resistant schizophrenia or a natural progression of the illness, prompting unnecessary dose escalations that deepen the very deficit it causes. Recognizing NIDS helps clinicians avoid a vicious cycle of over-medication and protects the patient's functional capacity and quality of life.
When was Neuroleptic-induced deficit syndrome first introduced, and who coined its name?
The underlying phenomenon was first described in 1975 by Arthur Rifkin and colleagues under the label 'akinesia,' referring to the motor and affective flattening they observed in over-treated patients. The formal term 'Neuroleptic-induced Deficit Syndrome' was coined in 1993 at the First International Meeting on the subject, chaired by Malcolm Lader.
More in Drug-induced diseases 1-20
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced